Lehmann W D, Musch K, Wolf A S
J Endocrinol Invest. 1979 Jul-Sep;2(3):251-5. doi: 10.1007/BF03350411.
The influence of bromocriptine, a prolactin antagonist, on maternal plasma and amniotic fluid prolactin (PRL) was investigated in two pregnancies at the 20th week with medical indication for abortion. Voluntary consensus of the patients was obtained. Blood sample determinations demonstrated that bromocriptine inhibits the secretion of PRL both in plasma and amniotic fluid. Since no changes were observed in peripheral maternal steroid concentrations of dehydroepiandrosterone, dehydroepiandrosterone-sulfate, delta 4-androstene-3, 17-dione, testosterone, estradiol, estriol, and cortisol, it is concluded that PRL does not seem to affect maternal and fetal adrenal cortex as supposed in amenorrhoic patients with hyperprolactinemia.
在两例妊娠20周因医学原因需终止妊娠的孕妇中，研究了催乳素拮抗剂溴隐亭对母体血浆和羊水催乳素（PRL）的影响。已获得患者的自愿同意。血样检测表明，溴隐亭可抑制血浆和羊水中PRL的分泌。由于未观察到母体外周脱氢表雄酮、硫酸脱氢表雄酮、Δ4-雄烯-3,17-二酮、睾酮、雌二醇、雌三醇和皮质醇等甾体激素浓度的变化，得出结论：催乳素似乎并不像高催乳素血症闭经患者所推测的那样影响母体和胎儿的肾上腺皮质。
